Replies to post #691 on Rock Creek Pharmaceuticals Inc (fka RCPIQ)

[LovePennies]

CIGX reminds James ALtucher of HANS 2000 to 2010 $0.56 to $60.00. James always said that he was thinking about doing another write up: http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_S/threadview?bn=100813&tid=21165&mid=21165

[shankapotamus]

They'll buy whatever they've been buying. lol... I can assure you my father will continue to buy Kodiak.

[shankapotamus]

Try again. Notice the underlined parts, but I would advise you read the entire document.

ITEM 1A.
RISK FACTORS
We have incurred losses for the past eight years and operating expenses are likely to continue to be greater than operating revenues in the foreseeable future.
We have incurred operating losses for eight consecutive fiscal years beginning with the year ended December 31, 2003. Our net losses were approximately $(18.3) million for the year ended December 31, 2008, $(22.8) million for the year ended December 31, 2009 and $(28.3) million for the year ended December 31, 2010. Our accumulated deficit as of December 31, 2010 was approximately $(170.7) million. Additionally, a majority of our historical operating revenues have been derived from sales of our discount cigarettes. However, in May 2007, we entered into a license agreement with Tantus for the exclusive license of our trademarks MainStreet®, Sport® and GSmoke®, in return for licensing fees during the seven-year term of the license agreement and beyond, if the license is renewed. Although we retain the right to manufacture and sell other branded cigarettes, we discontinued the manufacture and sale of our discount cigarettes in June 2007 and are focusing our efforts in the tobacco area on the sale of low-TSNA dissolvable smokeless tobacco products and the licensing of the related technology, as opposed to cigarettes. In August 2010, we introduced CigRx®, a non-nicotine, non-tobacco nutraceutical, in the Richmond, Virginia area. Sales of CigRx® were de minimis in 2010 and it would take a substantial increase in sales of CigRx® and our dissolvable tobacco products for operating revenues to exceed expenses.



18

Table of Contents

Our future prospects, therefore, are dependent on the expanded distribution and consumer acceptance of our low-TSNA dissolvable smokeless tobacco products as well as CigRx® our ability to support the expansion of the market for these products and the continued development of new low-TSNA smokeless tobacco products, related pharmaceutical products and nutraceuticals, independently and through alliances with other tobacco manufacturers or pharmaceutical companies. Our future results of operations are also dependent on our ability to begin generating significant revenues through royalties from the patented tobacco curing process to which we are the exclusive licensee. However, our ability to generate revenues through sales of our smokeless tobacco products and the licensing of related products will substantially be dependent on the successful completion of our ongoing patent infringement lawsuit against RJR.